Valuation: MacroGenics, Inc.

Market Cap 155M 139M 129M 117M 218M 14.8B 221M 1.54B 614M 7.75B 583M 571M 24.59B P/E 2026 *
-1.57x
P/E 2027 * -1.49x
Enterprise Value 155M 139M 129M 117M 218M 14.8B 221M 1.54B 614M 7.75B 583M 571M 24.59B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.72x
Free-Float
96.51%
Yield 2026 *
-
Yield 2027 * -
10-26 MacroGenics, Inc. Announces Positive Interim Phase 2 LINNET Results For Lorigerlimab In Advanced Clear Cell Gynecologic Cancer CI
10-23 MacroGenics, Inc. Announces Positive Interim Phase 1 Results For MGC026 And Plans To Initiate Front-Line Combination Study In SCCHN CI
10-16 MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors MT
10-15 MacroGenics, Inc. Announces First Patient Dosed In Phase 1 Study Of MGC030 In Patients With Advanced Solid Tumors CI
08-17 B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating MT
08-13 MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-11 Macrogenics, Inc. and Gilead Sciences, Inc. Announce Achievement of $10 Million Milestone Following Gilead Sciences, Inc.?S Exercise of Option to License Preclinical Bispecific Program CI
07-23 MacroGenics, Inc. Provides Clinical Update on Ongoing Phase 1 Study for MGC026 CI
07-08 Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026 CI
07-02 MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals MT
07-02 Bora Biologics USA, LLC completed the acquisition of Good Manufacturing Practice Drug Substance Manufacturing Operations of MacroGenics, Inc.. CI
06-29 MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark CI
06-29 MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell 2500 Growth Benchmark CI
1 day+1.23%
1 week-31.20%
Current month-36.01%
1 month-39.16%
3 months-35.84%
6 months-17.94%
Current year+53.42%
1 week 1.93
Extreme 1.93
3.67
1 month 1.93
Extreme 1.93
4.09
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
22.68
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 A Exercice

Chief Technology Officer

16,000 0.0251%
8/19/26 A Sell

General Counsel

-31,105 0.0489%
8/17/26 A Exercice

Chief Technology Officer

80,000 0.1259%
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%-31.20%+33.51%-52.13% 155M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+0.87%+27.92%+57.51% 44.75B
+2.00%-3.39%+17.83%+100.08% 41.62B
+1.34%-2.86%+224.43%+928.45% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.21%-3.39%+50.13%+141.27% 38.06B
Weighted average by Cap. +3.21%-0.30%+47.36%+161.21%

Financials

2026 *2027 *
Net sales 108M 97.07M 89.75M 81.28M 152M 10.3B 154M 1.07B 427M 5.39B 406M 397M 17.12B 90.61M 81.29M 75.16M 68.07M 127M 8.63B 129M 899M 358M 4.52B 340M 333M 14.34B
Net income -88.7M -79.58M -73.58M -66.64M -124M -8.45B -126M -880M -350M -4.42B -333M -326M -14.03B -138M -124M -115M -104M -194M -13.15B -196M -1.37B -545M -6.88B -518M -507M -21.85B
Net Debt - -
Projected Income Statement - Annual - MacroGenics, Inc.
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
28/10/26 $2.470 +1.23% 1,412,444
27/10/26 $2.440 +11.42% 2,120,069
26/10/26 $2.190 -2.67% 2,606,646
23/10/26 $2.250 -38.02% 4,009,664
22/10/26 $3.630 +1.11% 465,521
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MacroGenics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.440USD
Average target price
8.000USD
Spread / Average Target
+227.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MacroGenics, Inc.
  1. Stock Market
  2. Stocks
  3. MGNX Stock